We’ve curated some of the recent articles appearing on the NCI Cancer Currents Blog for you to review. Current topics include a wide range of areas in cancer research:
- Reducing Lung Cancer Stigma: Researchers at Memorial Sloan Kettering Cancer Center have developed a training program to help health providers reduce lung cancer stigma. An ongoing NCI-funded nationwide clinical trial is testing this training program1.
- Fructose and Cancer Growth: A lab study found that feeding fructose to lab animals with cancer made their tumors grow faster. The study is exploring how fructose, a main component of high-fructose corn syrup, indirectly fuels cancer growth through the liver1.
- FDA Approvals for Multiple Myeloma: The FDA has approved Darzalex Faspro and Sarclisa, each used in combination with standard three-drug treatment regimens. These approvals are expected to change the initial treatment of newly diagnosed multiple myeloma, including for patients who cannot undergo a stem cell transplant1.
- Experimental CAR T-Cell Therapy: An experimental CAR T-cell therapy targeting the protein GD2 has shown promise in shrinking tumors in children and young adults with diffuse midline glioma, an aggressive brain and spinal cord cancer. This small clinical trial reported tumor shrinkage lasting for 2 years or more in several cases1.
- Patient-Reported Outcomes in Pediatric Cancer: Two clinical trials have shown that younger cancer patients who filled out surveys about their symptoms experienced fewer cancer-related symptoms than those who did not complete the surveys. These findings highlight the importance of patient-reported outcome (PRO) surveys for children during treatment1.
- Cetuximab for Head and Neck Cancer: Findings from a recent NCI-supported clinical trial indicate that cetuximab outperforms durvalumab for patients with locally advanced head and neck cancer when cisplatin is not an option1.
These topics reflect the diverse and innovative research efforts currently underway to improve cancer treatment and patient care.



